Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice.
Nakashima Y, Kondo M, Shono E, Ishinishi T, Tsukamoto H, Kuroda K, Maeyama A, Harada H, Maekawa M, Shimauchi T, Nagamine R, Jojima H, Yoshizawa S, Tsuru T, Otsuka T, Miyahara H, Suematsu E, Wada K, Yoshizawa S, Inoue Y, Fukuda T, Ikemura S, Haraguchi A.
Nakashima Y, et al. Among authors: maeyama a.
Mod Rheumatol. 2020 Sep;30(5):807-815. doi: 10.1080/14397595.2019.1676369. Epub 2019 Oct 17.
Mod Rheumatol. 2020.
PMID: 31580188